Clinical Trials - Breast Cancer

• Sarah Cannon – BRE 43- 1st Relapse Metastatic Breast, DOxil Injection vs Taxotere, PH II

• CTSU - IBCSG25-02 - Premeopausal, Endocrine Responsive,Stg I -III, Post Op, Role of Hormones, PhIII

• CTSU - MA.27 - Postmenopausal, Endocrine Responsive, Hormones

• Sarah Cannon - BRE-63 - A Phase II Trial of Combination Gemcitabine, Carboplatin With Or Without Trastuzumab In Patients With Metastatic Breast Cancer

• A Single Site Prospective, Non randomized Study of the MammoSite® Radiation Therapy Delivery System (Breast Brachytherapy Applicator) To Evaluate Local Tumor Control, Cosmetic Outcome and Toxicities

• CTSU NSABP B-39 / RTOG 0413 - Phase III – Randomized Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer
  
  
• CTSU NSABP B-37 - Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast CA
  
  
• SWOG 0230 - Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
  
  
• CTSU NSABP B-36 - Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC) in Patients with Node-Negative Breast Cancer
  
  
• CTSU NSABP B-38 - Phase III, Adjuvant Trial Comparing Three Chemo Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide(TAC);Dose Dense (DD) Doxorubicin/Cyclophosphamide followed by DD Paclitaxel (DD AC→ P); DD AC followed by DD Paclitaxel plus Gemcitabine (DD AC →PG)
  
  
• Sarah Cannon– BRE 73 - Phase II Trial of Dose Dense Neoadjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced and/or Inflammatory Breast Cancer
  
  
• Sarah Cannon BRE 89 -PHASE II - VINFLUNINE WITH OR WITHOUT TRASTUZUMAB IN PATIENTS WITH METASTATIC BREAST CANCER
  
  
• CTSU – E2805 - Phase III - Randomized, Double-Blind Trial of Adjuvant Sunitinib vs Sorafenib vs Placebo in Patients w/ Resected RCC